Leerink Partnrs Has Bullish Forecast for Sanofi Q3 Earnings

Sanofi (NASDAQ:SNY - Free Report) - Equities researchers at Leerink Partnrs increased their Q3 2025 earnings estimates for Sanofi in a research report issued to clients and investors on Monday, July 7th. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings of $1.77 per share for the quarter, up from their prior forecast of $1.76. The consensus estimate for Sanofi's current full-year earnings is $4.36 per share. Leerink Partnrs also issued estimates for Sanofi's Q4 2025 earnings at $0.78 EPS.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The business had revenue of $10.41 billion for the quarter, compared to analysts' expectations of $9.79 billion. During the same quarter in the previous year, the business posted $1.78 earnings per share. The business's revenue was down 11.0% compared to the same quarter last year.

SNY has been the topic of a number of other research reports. Guggenheim reiterated a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. BNP Paribas started coverage on Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. Morgan Stanley set a $56.00 price objective on Sanofi in a research report on Monday, June 2nd. Finally, Barclays reaffirmed an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Sanofi currently has an average rating of "Buy" and an average price target of $61.50.

Sanofi Stock Performance

NASDAQ:SNY traded down $0.14 during midday trading on Tuesday, hitting $48.18. The company's stock had a trading volume of 2,426,885 shares, compared to its average volume of 2,338,732. Sanofi has a fifty-two week low of $45.80 and a fifty-two week high of $60.12. The firm's 50 day moving average is $50.52 and its 200-day moving average is $52.12. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.37 and a quick ratio of 0.69. The firm has a market cap of $118.16 billion, a P/E ratio of 17.21, a P/E/G ratio of 1.05 and a beta of 0.48.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were paid a $2.0369 dividend. This is a positive change from Sanofi's previous annual dividend of $1.48. This represents a yield of 3.1%. The ex-dividend date of this dividend was Friday, May 9th. Sanofi's dividend payout ratio is presently 57.14%.

Institutional Investors Weigh In On Sanofi

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Baker Ellis Asset Management LLC boosted its holdings in Sanofi by 2.1% in the second quarter. Baker Ellis Asset Management LLC now owns 95,794 shares of the company's stock valued at $4,628,000 after purchasing an additional 2,014 shares during the last quarter. NBC Securities Inc. increased its holdings in shares of Sanofi by 8.5% in the 2nd quarter. NBC Securities Inc. now owns 24,904 shares of the company's stock valued at $1,203,000 after purchasing an additional 1,953 shares during the period. Gradient Investments LLC boosted its stake in shares of Sanofi by 26.5% during the 2nd quarter. Gradient Investments LLC now owns 12,355 shares of the company's stock worth $597,000 after acquiring an additional 2,591 shares in the last quarter. Gallacher Capital Management LLC boosted its stake in Sanofi by 39.1% during the 2nd quarter. Gallacher Capital Management LLC now owns 8,796 shares of the company's stock valued at $425,000 after purchasing an additional 2,471 shares during the period. Finally, Voya Investment Management LLC raised its holdings in Sanofi by 11.6% in the 1st quarter. Voya Investment Management LLC now owns 206,635 shares of the company's stock valued at $11,460,000 after acquiring an additional 21,540 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.